5-HT2A SNPs Alter the Pharmacological Signaling of Potentially Therapeutic Psychedelics

ACS Chem Neurosci. 2022 Aug 17;13(16):2386-2398. doi: 10.1021/acschemneuro.1c00815. Epub 2022 Jul 27.

Abstract

Serotonin (5-hydroxytryptamine; 5-HT) 2A receptor (5-HT2AR) signaling is essential for the actions of classical psychedelic drugs. In this study, we examined whether sequence variations in the 5-HT2AR gene affect the signaling of four commonly used psychedelic drugs. We examined the in vitro pharmacology of seven non-synonymous single-nucleotide polymorphisms (SNPs), which give rise to Ser12Asn, Thr25Asn, Asp48Asn, Ile197Val4.47, Ala230Thr, Ala447Val, and His452Tyr variant 5-HT2A serotonin receptors. We found that these non-synonymous SNPs exert statistically significant, although modest, effects on the efficacy and potency of four therapeutically relevant psychedelics. Significantly, the in vitro pharmacological effects of the SNP drug actions at 5-HT2AR are drug specific.

Keywords: 5-HT2A; SNP; hallucinogen; polymorphism; psychedelic; serotonin receptors.

MeSH terms

  • Hallucinogens* / pharmacology
  • Polymorphism, Single Nucleotide / genetics
  • Receptor, Serotonin, 5-HT2A / genetics
  • Serotonin
  • Serotonin 5-HT2 Receptor Agonists / pharmacology
  • Signal Transduction

Substances

  • Hallucinogens
  • Receptor, Serotonin, 5-HT2A
  • Serotonin 5-HT2 Receptor Agonists
  • Serotonin